Leah, a molecular biologist and healthcare economist, discovered Leiden University’s prognostic marker research. The Leiden University team is renowned for expertise in coronary plaque research. Peer-reviewed findings of prospective studies of ER chest pain patients demonstrated prognostic markers detected early coronary plaque rupture predictive of a cardiac event within six months. Continued research reports the prognostic makers correlate to CT angiography, and cardiac stress testing. Armed with the exclusive license to the markers, XCellCure is dedicated toward a preventive approach to heart attack and CVD by expediting rapid portable point of care (POC) detection of the vague early symptoms using a patented novel multi-marker technique in trials for FDA clearance. “Today, we are the only company providing non-invasive quantitative data guiding preventive care for heart attack and cardiovascular diseases,” remarks Leah, Founder and CEO, XCellCure.
XCellCure’s AMiAware Human Cardiovascular Disease Microarray is an ingenious, non-invasive diagnostic test offering a novel prognosis of cardiac risk by detecting 13 circulating biomarkers in plasma reported on a patented rapid POC detection platform technology.
Today, we are the only company that provides noninvasive quantitative preventive care for cardiovascular diseases and heart attack
The biomarkers measure patient-specific signature of cardiac disease, providing prognostic quantitative information on the early changes of coronary vessels which, in turn, reports the earliest warning of a heart attack and cardiac tissue necrosis enabling preventive cardiac care.
Currently available for research purposes only, the AMiAware microarray kit aids understanding of drug therapy, interventions, and exercise on coronary vessels and cardiac tissue. One AMiAware kit reports biomarkers for 8-50 patients 4 hours from 50 uL of plasma. For a single patient analysis, XCellCure created the patented light weight, POC, detection platform using embedded sensors. Results against controls are obtained within 15-25 minutes at 1/10 of the cost of laboratory equipment. Once FDA cleared, AMiAware using a finger prick of blood will report the biomarkers at the POC, enabling rapid ER turnaround and field work anywhere.
AMiAware enables researchers to undertake a gamut of tasks at low cost, possibly reducing the incidence of CT angiography and cardiac stress testing. They can monitor patients with cardiac arrhythmia, generate a patient-specific cardiac tissue profile before chemotherapy, test the effectiveness of drug therapy, detect inflammatory syndromes and progression of COPD.
While XCellCure’s dedicated team of professionals is focused on enabling doctors to save lives, its cutting-edge and proprietary solution has been recognized by prominent medical institutions such as Prairie Heart Institute, Missouri Baptist Medical Center.
As it moves ahead, XCellCure has initiated discussions with Europe-based organizations to launch AMiAware European markets with plans to foray into China. XCellCure plans to incorporate other markers, collaborate with other companies that share business objectives, and license its technology to them. The company has also received interest for its platform technology to test water contaminants and other diseases. With its economical and cutting-edge solutions, XCellCure is set out to improve preventive heart care and save more lives.